Business
Zevra Therapeutics to Present Multiple Analyses on MIPLYFFA® at the 22nd Annual WORLDSymposium™
Four abstracts highlighting clinical data and real-world experience with MIPLYFFA accepted for presentation, including an oral presentation by Caroline Hastings, MD Company to host satellite symposium on diagnostic and therapeutic advances in Niemann-Pick disease type C (NPC) CELEBRATION, Fla., Jan. 26, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, today an
About this update from Zevra Therapeutics, Inc.
[{"type":"image","alt":"Zevra Therapeutics","displaySize":"","headline":null,"caption":"Zevra Therapeutics","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":80,"url":"https://media.zenfs.com/en/globenewswire.com/47aa28c5ce5943ac0fb423dcc40d01c5"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/BTrlkcW3K5pHsBf7HqZtVg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTExMjtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/47aa28c5ce5943ac0fb423dcc40d01c5","width":300,"height":80}},"lazy":false},{"type":"text","content":"Four abstracts highlighting clinical data and real-world experience with MIPLYFFA accepted for presentation, including an oral presentation by Caroline Hastings, MD","length":164,"tagName":"p"},{"type":"text","content":"Company to host satellite symposium on diagnostic and therapeutic advances in Niemann-Pick disease type C (NPC)","length":111,"tagName":"p"},{"type":"text","content":"CELEBRATION, Fla., Jan. 26, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, today announced that four abstracts discussing data and clinical experience associated with MIPLYFFA® (arimoclomol) have been accepted for presentation at the 22nd Annual WORLDSymposium™. Dr. Caroline Hastings will present four-year real-world safety and efficacy data of MIPLYFFA in patients with Niemann-Pick Disease Type C (NPC) during a podium presentation.","length":576,"tagName":"p"},{"type":"text","content":"The poster presentations include outcomes from the U.S. Early Access Program (EAP), multi-year subgroup analyses, and efficacy results from a randomized, placebo-controlled clinical trial, further expanding the body of evidence characterizing MIPLYFFA in pediatric and adult NPC patients. In addition, Zevra will host a non-continuing education (Non-CE) sponsored satellite symposium focused on diagnostic and therapeutic challenges in NPC.","length":440,"tagName":"p"},{"type":"text","content":"Podium Presentation Details","length":27,"tagName":"p"},{"type":"table","headerItems":[],"items":[{"val":[{"style":"max-width:15%;width:15%;min-width:15%;border-top:solid black 1pt;border-right:solid black 1pt;border-bottom:solid black 1pt;border-left:solid black 1pt;vertical-align:middle;text-align:left;padding-left:10.0px;ver...